Chimerix, Inc. (CMRX) Lowered to Hold at Zacks Investment Research
Chimerix, Inc. (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
CMRX has been the topic of several other reports. FBR & Co reissued a “hold” rating and set a $7.00 target price on shares of Chimerix in a research note on Monday, May 1st. Cowen and Company reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Friday, April 28th.
Shares of Chimerix (CMRX) traded down 6.11% during trading on Thursday, reaching $4.46. 270,412 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $5.17 and its 200-day moving average price is $5.45. The stock’s market cap is $209.83 million. Chimerix has a 52-week low of $3.66 and a 52-week high of $6.64.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. On average, equities research analysts forecast that Chimerix will post ($1.68) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/10/chimerix-inc-cmrx-lowered-to-hold-at-zacks-investment-research.html.
A number of large investors have recently made changes to their positions in CMRX. State Street Corp raised its stake in shares of Chimerix by 2.6% in the fourth quarter. State Street Corp now owns 751,031 shares of the biopharmaceutical company’s stock valued at $3,453,000 after buying an additional 18,688 shares during the last quarter. TFS Capital LLC acquired a new stake in shares of Chimerix during the first quarter worth $684,000. Bank of Montreal Can raised its stake in shares of Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,448 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Chimerix during the first quarter worth $776,000. Finally, Nationwide Fund Advisors raised its stake in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 1,977 shares during the last quarter. Institutional investors and hedge funds own 65.63% of the company’s stock.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.